Skip to main content
. 2019 May 31;24(11):2077. doi: 10.3390/molecules24112077

Figure 2.

Figure 2

Sarconesin II’s effect on toxicity assays. (a) Growth curve for E. coli DH5α incubated with sarconesin II MIC. Bacterial growth was inhibited at 240 min. (b) HeLa cell cytotoxicity measured by MTT tetrazolium assay. Cells were incubated with sarconesin II at 25, 50 and 100 μM for 24 h. Untreated HeLa cells were used as negative control and HeLa cells treated with 30% DMSO were used as positive control. (c) Hemolytic activity against human red blood cells (RBC). Sarconesin II was tested at 25, 50 and 100 μM concentrations. PBS was added without peptide for determining 0% hemolysis. The arrow indicates the concentration at which the fraction had antimicrobial activity. The average of each experiment done in triplicate is presented in individual columns as mean ± SD. One-way ANOVA followed by post hoc Dunnett’s multiple comparison test was used. *** p < 0.001.